Two growth hormone peptides, built by two companies in the same city, at the same time, for the same condition, using the exact same natural hormone as their starting point. In July 2006, one company's trial was halted after a participant died. The other company's trial, treating the same disease, kept going. One became an FDA-approved medicine. The other is now a research-chemical bestseller that a federal safety panel formally rejected for pharmacy use just last year.

This week I walk through how these peptides actually work, why two companies took completely different approaches to stabilising the same fragile hormone, and why that one event in 2006 sent them down permanently different paths. I get into why one of them became a tightly-controlled "biologic" and the other never could, what HIV-related fat redistribution actually is and why a growth-hormone peptide made genuine medical sense as a treatment for it, and the part most coverage skips: even the approved drug doesn't protect you if what you're actually buying never went anywhere near the trials that proved it works. I also cover the real physiology of how raising growth hormone affects blood sugar, and what the evidence shows if you're already starting from normal levels.

Sources: Falutz et al., NEJM 2007 & JCEM 2010; Ionescu et al., JCEM 2006; FDA Pharmacy Compounding Advisory Committee, December 2024; Stanley et al., Lancet HIV 2019; Baker et al., Archives of Neurology 2012; Rudman et al., NEJM 1990.

This is informational purposes only, not medical advice. If you can't get seen by your own physician, by all means do so, but always speak to your own healthcare provider. New episodes every week.

Most people asking about a peptide want to know one thing: does it work. That's not actually the first question you should be asking — and this week I walk through the checklist that should come before it, the one almost nobody follows, including plenty of people already using these products.

I cover the five questions worth asking before you put any peptide in your body, then spend most of the episode on what actually determines whether it's safe: how to read a Certificate of Analysis properly, why the two most-trusted names in peptide testing aren't accredited to any recognised standard, and why the pricing structure of this industry quietly rewards vendors for skipping the tests that matter most. I also get into a recent finding that changed how I think about sourcing entirely — some of the same manufacturers producing fentanyl precursors have been pivoting directly into the peptide supply chain. That's not a reason to panic about every vial, but it's exactly the kind of thing a purity percentage will never tell you.

Sources: Peter Attia, MD, The Peter Attia Drive Ep. #387 (AMA #83); UKAS/A2LA/NATA accreditation standards; FDA 21 CFR Parts 210 & 211; ICH Q2(R2)/Q14; Axios, July 2026, on the fentanyl-to-peptide supply chain. Website for the testing I discussed- Janoshik.com

This is informational purposes only, not medical advice. If you can't get seen by your own physician, by all means do so, but always speak to your own healthcare provider. New episodes every week.

There's a weight-loss drug right now producing the biggest numbers ever recorded in an obesity trial. It hasn't been approved by a single regulator anywhere in the world. And it's already being injected by thousands of people, sourced from vendors who have no legal right to sell it for human use.

This week I explain how that's actually possible — starting with a patent-law loophole that let an unapproved molecule's exact structure become public years before its own trials even finished. I get into why licensed pharmacies genuinely can't legally compound this drug, no matter what a website claims, and I walk through the actual pharmacology behind it: how GLP-1, GIP, and glucagon each work on their own receptors, and why building a weight-loss drug around a hormone that classically raises blood sugar is a deliberate, calculated trade-off rather than a mistake. Then I get into the real Phase 2 trial data — the actual serious adverse event cases, not just the headline weight-loss percentage — and what real-world users are self-reporting on forums like Reddit, which doesn't match the clinical trial data at all. That mismatch raises some uncomfortable questions about what's actually in these vials.

Sources: Jastreboff et al., NEJM 2023 (Phase 2 trial); Coskun et al., Cell Metabolism 2022 (receptor pharmacology); Sanyal et al., Nature Medicine 2024 (liver fat data); Salhab et al., Endocrine Society 2025 (network meta-analysis); Sehgal/Tronieri et al., medRxiv 2026 (Reddit self-report study); Eli Lilly TRIUMPH-1 through -4 topline results, 2025-2026.

This is informational purposes only, not medical advice. If you can't get seen by your own physician, by all means do so, but always speak to your own healthcare provider. New episodes every week.

BPC-157 is the poster child for the peptide boom, and I want to be upfront: I'm not against peptides on principle — insulin and GLP-1 medications are peptides too. What matters is how something's produced, how it's used, and whether the evidence actually supports it. This episode is me working through BPC-157 properly, using that exact standard.

I start with how clinical trials actually work, since that's the real dividing line between a regulated medicine and everything else. Then I go into BPC-157's own origin story — discovered in 1989, first reported in 1993, with the discoverers' own patent filing admitting they may not have isolated one single pure compound. I cover both proposed mechanisms currently in the literature, which don't yet connect to each other, then the animal evidence, which is real but concentrated heavily in one research group.

The human evidence is where this gets serious: three small pilot studies exist, all from the same investigator, covering roughly 30 people total, none controlled. I go through exactly what each one found, and why 87.5% and 80-100% headline figures don't mean what they sound like without a comparison group. Then I compare all of that to how people are actually dosing this at home, and where that convention really comes from — it isn't from any human trial.

I finish with the July 2026 FDA advisory committee vote, what it actually changes and what it doesn't, and my own honest verdict on where this stands right now.

Studies & Sources: Sikiric et al. (1993, original patent/Journal of Physiology); Sikiric et al. (1994, Life Sciences); Hsieh et al. (2016, Journal of Molecular Medicine); Seiwerth & Sikiric et al. (2021, Frontiers in Pharmacology); Vasireddi et al. (2025, Sports Health/HSS, PMID 40756949); Józwiak et al. (2025, Pharmaceuticals); Zhang, Liu, Ou et al. (2026, Cell Communication and Signaling); Lee & Padgett (2021); Lee, Walker & Ayadi (2024); Lee & Burgess (2025, Alternative Therapies in Health and Medicine, PMID 40131143); FDA Pharmacy Compounding Advisory Committee meeting, July 2026.

Informational only, not medical advice. New episodes of A Modern Pharmacist drop weekly.

Magnesium supplements are everywhere right now, and I wanted to know whether I actually needed one myself. This episode is the result of about three months of genuinely digging into the evidence — not just repeating what supplement companies say.

I start with why magnesium matters mechanistically: it has to be bound to ATP to function properly, and it plays a direct role in insulin signalling, which is what first got my attention. I explain why a standard blood test only reflects about 1% of your total body magnesium, and why that makes true deficiency genuinely hard to diagnose with any confidence.

The centre of this episode is the absorption question. Supplement labels frequently claim up to 80% bioavailability for organic forms like bisglycinate — but when I looked at the actual controlled research, the real figures are dramatically lower, and I walk through exactly why, including a genuine flaw in how that research was conducted. I also explain "buffering" — why some supplements quietly blend in cheap magnesium oxide alongside the organic form you're paying for, and how to spot it on a label.

I cover who's genuinely at higher risk of deficiency, why food supplements aren't held to the same manufacturing standard as medicines, and the one magnesium product that actually is a licensed medicine in the UK. I finish with exactly what I've personally decided to buy, and why.

Studies & Sources: Attia's AMA #54 on magnesium (background source); Firoz & Graber (2001, Magnesium Research) on bioavailability; Pełczyńska et al. (2022, Nutrients) on magnesium and metabolic disorders; Nielsen & Lukaski (2006) on exercise and magnesium; Liu et al. (2016) and Zhang et al. (2022) on magnesium L-threonate and cognition; Held et al. (2002) on magnesium and sleep; UK food supplement labelling tolerance guidance (FSA); Magnaspartate SmPC (electronic Medicines Compendium).

Informational only, not medical advice. New episodes of A Modern Pharmacist drop weekly.

I'm going through my own hair loss treatment right now, so this episode is a bit more personal than usual. I walk through my own thinking on minoxidil and finasteride — the two main evidence-backed treatments — and why I've made the choice I have.

Before we get to treatment, I cover what you need to rule out first: telogen effluvium from stress, iron deficiency, thyroid disorders, and B12/vitamin D deficiency. I also debunk the "check your mum's dad" myth for predicting hair loss — the real genetics are polygenic, not a single inherited trait.

Then I get into the mechanisms: how minoxidil increases blood flow via vasodilation and why some people don't respond to it (a sulfotransferase enzyme issue), and how finasteride blocks the conversion of testosterone to DHT. I explain the genuinely strange DHT paradox — the same hormone shuts down hair growth on your scalp but promotes it on your beard and body — and why chasing a "zero DHT" target makes no sense clinically.

Because this is a cosmetic rather than a life-or-death condition, I talk openly about how that should shift your risk tolerance around finasteride's side-effect profile, and why I've personally chosen to stick with topical minoxidil for now.

Sources: Hamilton (1951, prevalence data via Endotext), Chumlea et al. 2004 (family history risk), Gupta et al. 2022 (minoxidil/finasteride hair count meta-analysis), Drake et al. 1999 (finasteride scalp DHT suppression data).

This is informational purposes only, not medical advice. If you can't get seen by your own physician, by all means do so, but always speak to your own healthcare provider. New episodes every week.

Testosterone replacement therapy is one of the most searched, most misunderstood treatments in men's health. I go through what the evidence actually shows: the genuine benefits, the real risks, the flawed studies that shaped 15 years of unnecessary fear, and exactly when treatment is justified.

I start with the core diagnostic principle: the endocrine system is symptom-led, so a low number alone is never a diagnosis. True testosterone deficiency, once you require both a confirmed low level and real symptoms, affects only around 2% of men, mostly those over 60. I explain why free testosterone, not total testosterone, is the metric that actually matters, since only 1 to 4% of circulating testosterone is biologically active.

On benefits, I cover the genuinely well-documented structural effects: lean mass gains, fat loss, and real increases in bone mineral density that surprised even leading researchers who assumed bone density couldn't be influenced this way. I also cover the metabolic benefits, including a 40% reduction in progression to type 2 diabetes in one major trial.

On risk, I walk through the two badly flawed studies from 2013 and 2014 that wrongly linked TRT to heart attacks and strokes, including one that accidentally included women in a study meant to be all-male, and explain what the properly powered TRAVERSE trial actually found a decade later. I also cover the real prostate cancer picture, and go deep on fertility, including the mechanism behind why hCG and clomiphene work completely differently to preserve it.

Studies and Sources:

Prevalence and diagnosis: EMAS, the European Male Ageing Study.

Structural and metabolic benefits: Amory et al., JCEM 2004, bone density; Page et al., JCEM 2005, body composition; Snyder et al., JAMA Internal Medicine 2017, bone density and strength; Cai et al. 2014, metabolic meta-analysis; Wittert et al., Lancet Diabetes and Endocrinology 2021, the T4DM trial; Yassin et al. 2016, continuous versus interrupted TRT.

Cardiovascular controversy, the flawed studies: Vigen et al., JAMA 2013; Finkle et al., PLOS ONE 2014; Basaria et al., NEJM 2010; Xu et al., BMC Medicine 2013; Morgentaler et al., Mayo Clinic Proceedings 2015, critical re-analysis.

Cardiovascular, the better evidence: Corona et al., JCEM 2018; Wallis et al., Lancet Diabetes and Endocrinology 2016; Lincoff et al., NEJM 2023, the TRAVERSE trial.

Prostate cancer: multiple systematic reviews, 2004, 2008, 2009; TRAVERSE trial prostate sub-data.

Fertility and HPG axis: classic hypothalamic-pituitary-gonadal axis physiology; intratesticular versus serum testosterone concentration data.

Background and framing: Peter Attia, AMA number 28, All Things Testosterone and Testosterone Replacement Therapy, the Peter Attia Drive podcast, 2021.

Informational only, not medical advice. New episodes of A Modern Pharmacist drop weekly.

Statins are the most prescribed and most controversial medication on the planet. I am not debating whether they work, the evidence there is unambiguous. Instead I go deep on the two concerns patients raise with me most often: do statins cause type 2 diabetes, and do they harm your brain?

On diabetes, I walk through a genuinely new mechanism discovered in 2024: statins alter specific gut bacteria, which reduces a bile acid called UDCA, which in turn lowers GLP-1 and worsens glucose tolerance. There is already a trial underway testing whether supplementing UDCA can fix this without losing the cholesterol lowering benefit. I also cover the real numbers, how many people develop diabetes per statin users treated, weighed against heart attacks and strokes prevented, and why higher intensity statins carry more risk than lower doses.

On cognition, I explain why the brain being cholesterol rich does not mean statins starve it, since the brain has its own separate, protected cholesterol supply, and where the 2012 FDA warning about cognitive impairment actually came from versus what the trial evidence has consistently shown since. I also bring in the STAREE trial, published just days before recording this episode.

Finally, I explain why this question just became more urgent: 2026 guideline changes now make statins a consideration from age 30, and what that means for an evidence base built on trials lasting a fraction of that exposure window.

Studies and Sources:

Mechanism, diabetes: She et al., Cell Metabolism 2024, 36(2), 408-421. NCT06684106, ongoing UDCA plus atorvastatin trial. Nature Reviews Endocrinology 2015, the diabetogenic action of statins. Diabetologia 2006, statins and adipocyte GLUT4. J Clin Invest 2011, adiponectin and AMPK pathways. J Cell Physiol 2019, mechanisms of statin induced new onset diabetes.

Outcome evidence, diabetes: Sattar et al., Lancet 2010, 375, 735-742. Preiss et al., JAMA 2011, 305(24), 2556-2564. IPD meta-analysis, Lancet Diabetes and Endocrinology 2024. Ridker et al., Lancet 2012, JUPITER post-hoc analysis. Cleveland Clinic Journal of Medicine review 2023. NICE NG238 evidence review.

Benefit versus risk: CTT Collaboration meta-analysis, 26 trials, over 170,000 patients, Lancet 2012. TheNNT.com, statins in low cardiovascular risk primary prevention. Collins et al., Lancet 2016, interpretation of statin efficacy and safety evidence.

Outcome evidence, cognition: Cochrane review, statins for the prevention of dementia, HPS and PROSPER pooled. Zhou et al., JACC 2021, ASPREE trial. Ott et al., J Gen Intern Med 2015. Observational meta-analysis, European Journal of Preventive Cardiology 2022, 29(5), 804. Westphal Filho et al., Alzheimers and Dementia TRCI 2025. GeroScience 2026, brain, benefit or burden. STAREE trial, NEJM and ESC Congress 2026. PREVENTABLE trial, ongoing, Duke Clinical Research Institute.

Guideline context: 2026 multi-society dyslipidaemia guideline, ACC, AHA and nine other societies, March 2026. Eligibility study, JAMA, July 2026, Pittsburgh and VA, NHANES data. LDL cumulative exposure hypothesis paper, 2024.

Brain cholesterol mechanism: Tom Dayspring, Peter Attia podcast episodes 334 and 395, brain lipidology and cholesterol homeostasis.

Informational only, not medical advice. New episodes of A Modern Pharmacist drop weekly.

Everyone knows GLP-1 pens for weight loss and type 2 diabetes. What most people don't know is these drugs are now licensed — or being actively trialled — for at least eight other conditions, some of which genuinely surprised me while researching this one.

I sort them into three categories based on how confident the evidence actually is. The first: conditions where the benefit tracks almost perfectly with weight loss — obstructive sleep apnea, MASH (fatty liver disease), and a specific type of heart failure. The second: conditions where weight loss explains some but not all of the benefit — cardiovascular risk reduction, which is already licensed in the UK, and chronic kidney disease, where the benefit stops making sense purely in terms of blood sugar control. The third and most interesting: two conditions — a rare brain pressure disorder and alcohol use disorder — where the evidence points to a completely separate mechanism, likely involving dopamine and reward pathways rather than weight or glucose at all.

I also talk through a real patient case, a 27-year-old with a BMI of 46 and fatty liver disease, and where I think this field is heading next — including retatrutide and new drugs designed to protect muscle mass during GLP-1-driven weight loss.

Studies & Sources: SURMOUNT-OSA (Malhotra et al., NEJM 2024); ESSENCE (Sanyal et al., NEJM 2025); STEP-HFpEF (Kosiborod et al., NEJM 2023) and SUMMIT (Packer et al., NEJM 2025); SELECT (Lincoff et al., NEJM 2023); FLOW (Perkovic et al., NEJM 2024); Mitchell et al. (Brain, 2023) on IIH; SEMALCO (Klausen et al., Lancet 2026); framework adapted from Peter Attia's "GLP-1 Medications Beyond Weight Loss" (2026).

Informational only, not medical advice. New episodes of A Modern Pharmacist drop weekly.

Insulin resistance gets thrown around online like it's simple. It's genuinely one of the most complex mechanisms in metabolic health, and in this episode I break it down properly using the two researchers whose work most of our current understanding is built on — Ralph DeFronzo and Gerald Shulman.

I start with DeFronzo's "Ominous Octet" — the eight separate organs and tissues involved in insulin resistance, which is exactly why no single drug or intervention will ever fix it on its own. Then I go into the actual cellular mechanism: how fat builds up inside muscle cells specifically, physically blocking the pathway that lets glucose into the cell, and why your bloods can look completely normal for 10-15 years while insulin is quietly climbing behind the scenes to compensate.

I cover the liver's surprising role in continuing to produce glucose even when there's already too much in the blood, why the kidney does the opposite of what you'd expect, and I share a personal example from my own continuous glucose monitor after a single bad night's sleep that genuinely surprised me.

Finally, I go through what actually works: weight loss, cutting back refined carbs and saturated fat, prioritising sleep, zone 2 training specifically for improving fat-burning capacity, and building muscle mass as a genuine metabolic buffer.

Studies & Sources: DeFronzo (2009, Banting Lecture, Diabetes journal); Gerald Shulman's body of work on diacylglycerol/PKC-mediated insulin resistance; classic research on brain glucose use during starvation; incretin (GLP-1/GIP) physiology; sleep restriction and insulin sensitivity research.

Informational only, not medical advice. New episodes of A Modern Pharmacist drop weekly.